- Previous Close
25.15 - Open
24.50 - Bid --
- Ask --
- Day's Range
24.35 - 24.50 - 52 Week Range
22.90 - 36.35 - Volume
487 - Avg. Volume
3,194 - Market Cap (intraday)
422.772M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
17.90 - EPS (TTM)
1.36 - Earnings Date Apr 3, 2025
- Forward Dividend & Yield 1.35 (5.37%)
- Ex-Dividend Date Jun 3, 2024
- 1y Target Est
27.00
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
www.boiron.fr2,788
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BOI.PA
View MorePerformance Overview: BOI.PA
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BOI.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BOI.PA
View MoreValuation Measures
Market Cap
436.66M
Enterprise Value
398.18M
Trailing P/E
18.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.91
Price/Book (mrq)
1.17
Enterprise Value/Revenue
0.83
Enterprise Value/EBITDA
7.12
Financial Highlights
Profitability and Income Statement
Profit Margin
4.92%
Return on Assets (ttm)
4.41%
Return on Equity (ttm)
4.85%
Revenue (ttm)
481.71M
Net Income Avi to Common (ttm)
23.69M
Diluted EPS (ttm)
1.36
Balance Sheet and Cash Flow
Total Cash (mrq)
53.33M
Total Debt/Equity (mrq)
3.98%
Levered Free Cash Flow (ttm)
28.62M